Tuning Materials. Enhancing Lives. Tonny Voermans, M.Sc.

Managing Director

confidential

2

The issues of cure ▲ Drugs and medical devices become more advanced, but

still pose challenges

▲ Another issue is suboptimal handling of the device

▲ Current issues are: ▲ Complex diseases with a variety of causes and treatments

▲ Overmedication (of antibiotics)

▲ Extensive cure need due to hospitalization

confidential

3

Mission ▲ Improve the treatment options for patient and surgeon

▲ Improved working ▲ Longer efficacy (degradation)

▲ Target release

▲ Enhanced handling ▲ Better applicators

▲ Extension application areas ▲ Change functional form

confidential

4

Elements as innovation ▲ New technologies offer new treatment solutions

▲ Biopolymers are used as devices or carriers for drugs or tissues: viscosupplements and hemostasis products

▲ BioMed Elements has a technology platform to optimize the behavior of medical devices by tuning the basic elements of the polymers

confidential

5

Examples Biopolymers

Gelatine Hyaluronic Acid

Collagen

Chitosan

Alginate

Cellulose

Soy

confidential

6

Biomaterials market Market Size CAGR

Biomaterials 70 B 16%

Plastic surgery 6,5 B 14%

Orthopaedic 22 B 5%

Dental 6,6 B 7%

Hemostasis 1,5 B 4%

Tissue engineering 2,1 B 10%

The key market players are Royal DSM, Wright Medical Technology, Inc., Corbion N.V., Zimmer Biomet Holdings, Inc., Bayer AG, Carpenter Technology Corporation, Covalon Technologies Ltd., BASF SE, Invibio Ltd., Berkeley Advanced Biomaterials, Inc., and Collagen Matrix, Inc. among others.

http://www.biomatin.eu/pdf/Regional_analysis_of_the_biomaterial_market.pdf http://providencehightech.com/biomaterials-trends-forecasts/

confidential

7

BioMed Core Technology

Source Material Core Technology Spherical Submicron Particles

▲ Access to well defined spherical submicron particles

▲ Control over parameters (e.g. size, density)

▲ Patented continuous process:

▲ Upscaling is possible

▲ High consistent quality

1µm

confidential

8

Functional Forms

Suspension Powder Gel Sponge

Resorbable Hemostat Resorbable Scaffold Flowable Carrier

Application: Application: Application: Application:

Drug Carrier

Application Areas: orthobiologics, wound management, tissue engineering, medical aesthetics and cosmetics.

confidential

9

Business model ▲ Contract research and co-development:

▲ Feasibility study and product optimization

▲ Analytical study

▲ Contract manufacturing: ▲ Medical devices and half fabricates manufacturing

▲ Development own product range: ▲ Developing a range of niche products

confidential

10

Value proposition

Phase 1: Feasibility study for improved or new product

Phase 2: Proof of concept; lock in of IP

Phase 3: Upscaling of manufacturing based on BioMed expertise and manufacturing capabilities

Phase 4: Manufacturing and distribution of device

confidential

11

Current partners ▲ Netherlands: HCM Medical, Avivia, Fibriant, Leader

Biomedical and Zuyderland hospital.

▲ Europe: Mathys Medical (Switzerland), OST Developpement (France) and Sirakoss (United Kingdom).

▲ USA: Pro-Tech Design, Alamo Tissue Services, Synergy BioMedical, Celling Biosciences and Vivex Biomedical.

confidential

12

Development route ▲ Phase 1: Hemostatic range

▲ Hemostatic gel for various applications

▲ Sponge for heavy bleedings with active

confidential

13

Development route ▲ Scenario 2: Hyaluronic acid products

▲ Dermal filler

▲ Viscosupplement

confidential

14

Do’s and don’ts ▲ Be stubborn, but also look for people who are even more

stubborn

▲ Be smart on how to persuade investors

▲ Hold perspective on success; by yourself as well as from others

▲ Use network opportunities

▲ Luck = your effort + what others help you with

confidential

15

BioMed’s future ▲ Investment need for validation of haemostatic gel

▲ Set up and strengthen partner network

▲ Perform animal study for heavy bleedings product Q2 2018

▲ Market access in ENT surgery products

And what the future brings

“Tuning Materials. Enhancing Lives.”